David Calvet Canut on Takeda’s HyHub: A Shift Toward Patient-Centered Biologics
David Calvet Canut, Director TFE at UNIR, shared on LinkedIn:
“Takeda’s new HyHub™ system for HYQVIA® represents a significant advancement in patient-centered plasma-derived therapies. By simplifying subcutaneous immunoglobulin infusions, it enhances convenience and treatment adherence—areas where even small innovations can lead to meaningful improvements.
For biotech companies, this serves as a reminder that value creation now extends beyond just the molecule itself. Integration of devices, enhancement of patient experience, and home-based delivery are becoming crucial factors for competitive differentiation and securing reimbursement.
The field of plasma-derived therapies continues to evolve, and these hybrid therapy-plus-device models have the potential to redefine how we design, finance, and scale future biologics.”
Read full paper here.
Stay informed with Hemostasis Today.
-
Feb 25, 2026, 13:36Zoltan Nagy: Antibody Response Can Shift from Recognizing the Adenoviral Protein to Targeting PF4 in Rare VITT Cases
-
Feb 25, 2026, 13:08Sam K. Saha: Same Clot Against Fast and Slow Systems
-
Feb 25, 2026, 13:04Haykaz Muradyan: The Use of REBOA in Obstetric Haemorrhage
-
Feb 25, 2026, 12:53Jan Hartmann: NexSys Plasma Collection System Receives FDA Clearance
-
Feb 25, 2026, 12:45Zain Khalpey: Secondary Stroke Prevention as The Most Important Opportunity to Reduce Disability
-
Feb 25, 2026, 12:40Jeff June: Stroke Care Is Clinically Mature, Stroke Biology Is Still Evolving
-
Feb 25, 2026, 12:36Wolfgang Miesbach: Repurposing Metformin – From Sugar Control to Thrombus Control
-
Feb 25, 2026, 12:30Bethany Brown: There Is A Need for A Validated Replacement for The Discontinued 2,3-DPG Assay
-
Feb 25, 2026, 12:20Register for A Webinar on von Willebrand Disease in Ageing – EHC